Top

Published in:

01-03-2014 | Invited Review

Tissue prognostic biomarkers in primary cutaneous melanoma

Authors: Mario Mandalà, Daniela Massi

Published in: Virchows Archiv | Issue 3/2014

Abstract

Cutaneous melanoma (CM) causes the greatest number of skin cancer-related deaths worldwide. Predicting CM prognosis is important to determine the need for further investigation, counseling of patients, to guide appropriate management (particularly the need for postoperative adjuvant therapy), and for assignment of risk status in groups of patients entering clinical trials. Since recurrence rate is largely independent from stages defined by morphological and morphometric criteria, there is a strong need for identification of additional robust prognostic factors to support decision-making processes. Most data on prognostic biomarkers in melanoma have been evaluated in tumor tissue samples by conventional morphology and immunohistochemistry (IHC) as well as DNA and RNA analyses. In the present review, we critically summarize main high-quality studies investigating IHC-based protein biomarkers of melanoma outcome according to Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)-derived criteria. Pathways have been classified and conveyed in the “biologic road” previously described by Hanahan and Weinberg. Data derived from genomic and transcriptomic technologies have been critically reviewed to better understand if any of investigated proteins or gene signatures should be incorporated into clinical practice or still remain a field of melanoma research. Despite a wide body of research, no molecular prognostic biomarker has yet been translated into clinical practice. Conventional tissue biomarkers, such as Breslow thickness, ulceration, mitotic rate and lymph node positivity, remain the backbone prognostic indicators in melanoma.

Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, Grob JJ, Malvehy J, Newton-Bishop J, Stratigos A, Pehamberger H, Eggermont A (2010) Diagnosis and treatment of melanoma: European consensus-based interdisciplinary guideline. Eur J Cancer 46:270–283PubMed

World Health Organization. Skin cancers (2013) http://www.who.int/uv/faq/skincancer/en/index1.html. Accessed 28 June 2013

Jemal A, Siegel R, Xu J, Ward E (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMed

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, Eggermont AM, Flaherty KT, Gimotty PA, Kirkwood JM, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sober AJ, Sondak VK (2009) Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27:6199–6206PubMedCentralPubMed

Gimotty PA, Guerry D, Ming ME, Elenitsas R, Xu X, Czerniecki B, Spitz F, Schuchter L, Elder D (2004) Thin primary cutaneous malignant melanoma: A prognostic tree for 10-year metastasis is more accurate than American joint committee on cancer staging. J Clin Oncol 22:3668–3676PubMed

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: The next generation. Cell 144:646–674PubMed

McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer 93:387–391PubMedCentralPubMed

McShane LM, Hayes DF (2012) Publication of tumor marker research results: The necessity for complete and transparent reporting. J Clin Oncol 30:4223–4232PubMedCentralPubMed

10.

Altman DG, McShane LM, Sauerbrei W, Taube SE (2012) Reporting recommendations for tumor marker prognostic studies (REMARK): Explanation and elaboration. PLoS Med 9:e1001216PubMedCentralPubMed

11.

Gould Rothberg BE, Bracken MB, Rimm DL (2009) Tissue biomarkers for prognosis in cutaneous melanoma: A systematic review and metaanalysis. J Natl Cancer Inst 101:452–474PubMed

12.

Schramm SJ, Mann GJ (2011) Melanoma prognosis: A REMARK-based systematic review and bioinformatic analysis of immunohistochemical and gene microarray studies. Mol Cancer Ther 10:1520–1528PubMed

13.

Callender GG, Gershenwald JE, Egger ME, Scoggins CR, Martin RC 2nd, Schacherer CW, Edwards MJ, Urist MM, Ross MI, Stromberg AJ, McMasters KM (2012) A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: Comparison with the American joint committee on cancer model. J Am Coll Surg 214:608–617, discussion 617–619PubMed

14.

Soong SJ, Ding S, Coit D, Balch CM, Gershenwald JE, Thompson JF, Gimotty P (2010) Predicting survival outcome of localized melanoma: An electronic prediction tool based on the AJCC melanoma database. AJCC melanoma task force. Ann Surg Oncol 17:2006–2014PubMed

15.

MacKie RM, Aitchison T, Sirel JM, McLaren K, Watt DC (1995) Prognostic models for subgroups of melanoma patients from the Scottish melanoma group database 1979–86, and their subsequent validation. Br J Cancer 71:173–176PubMedCentralPubMed

16.

Schuchter L, Schultz DJ, Synnestvedt M, Trock BJ, Guerry D, Elder DE, Elenitsas R, Clark WH, Halpern AC (1996) A prognostic model for predicting 10-years survival in patients with primary melanoma. The Pigmented Lesion Group. Ann Intern Med 125:369–375PubMed

17.

Sahin S, Rao B, Kopf AW, Lee E, Rigel DS, Nossa R, Rahman IJ, Wortzel H, Marghoob AA, Bart RS (1997) Predicting ten-year survival of patients with primary cutaneous melanoma: A corroboration of a prognostic model. Cancer 80:1426–1431PubMed

18.

Breslow A (1970) Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172:902–908PubMedCentralPubMed

19.

Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, Foshag LJ, Cochran AJ (1992) Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 127(4):392–399

20.

Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, Saksena G, Stransky N, Onofrio RC, Winckler W, Ardlie K, Wagle N, Wargo J, Chong K, Morton DL, Stemke-Hale K, Chen G, Noble M, Meyerson M, Ladbury JE, Davies MA, Gershenwald JE, Wagner SN, Hoon DS, Schadendorf D, Lander ES, Gabriel SB, Getz G, Garraway LA, Chin L (2012) A landscape of driver mutations in melanoma. Cell 150(2):251–263

21.

Barnhill RL, Fine JA, Roush GC, Berwick M (1996) Predicting five-year outcome for patients with cutaneous melanoma in a population-based study. Cancer 78:427–432PubMed

22.

Allen AC, Spitz S (1953) Malignant melanoma; a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer 6:1–45PubMed

23.

Azzola MF, Shaw HM, Thompson JF, Soong SJ, Scolyer RA, Watson GF, Colman MH, Zhang Y (2003) Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3,661 patients from a single center. Cancer 97:1488–1498PubMed

24.

Gimotty PA, Elder DE, Fraker DL, Botbyl J, Sellers K, Elenitsas R, Ming ME, Schuchter L, Spitz FR, Czerniecki BJ, Guerry D (2007) Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 25:1129–1134PubMed

25.

Thompson JF, Soong SJ, Balch CM, Gershenwald JE, Ding S, Coit DG, Flaherty KT, Gimotty PA, Johnson T, Johnson MM, Leong SP, Ross MI, Byrd DR, Cascinelli N, Cochran AJ, Eggermont AM, McMasters KM, Mihm MC Jr, Morton DL, Sondak VK (2011) Prognostic significance of mitotic rate in localized primary cutaneous melanoma: An analysis of patients in the multi institutional American joint committee on cancer melanoma staging database. J Clin Oncol 29:2199–2205PubMedCentralPubMed

26.

Scolyer RA, Thompson JF (2013) Mitotic rate in melanoma should be recorded as the number of mitoses per mm(2) (not per high power field): surgeons tell your pathologists! Am J Surg 206:142–143PubMed

27.

In 't Hout FE, Haydu LE, Murali R, Bonenkamp JJ, Thompson JF, Scolyer RA (2012) Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. Ann Surg 255:1165–1170PubMed

28.

Klein G, Klein E (2005) Surveillance against tumors: Is it mainly immunological? Immunol Lett 100:29–33PubMed

29.

Day CL Jr, Sober AJ, Kopf AW, Lew RA, Mihm MC Jr, Golomb FM, Postel A, Hennessey P, Harris MN, Gumport SL, Raker JW, Malt RA, Cosimi AB, Wood WC, Roses DF, Gorstein F, Fitzpatrick TB (1981) A prognostic model for clinical stage I melanoma of the trunk: Location near the midline is not an independent risk factor for recurrent disease. Am J Surg 142:247–251PubMed

30.

Clark WH Jr, Elder DE, Guerry D 4th, Braitman LE, Trock BJ, Schultz D, Synnestvedt M, Halpern AC (1989) Model predicting survival in stage I melanoma based on progression. J Natl Cancer Inst 81:1893–1904PubMed

31.

Clemente CG, Mihm MC Jr, Bufalino R, Zurrida S, Collini P, Cascinelli N (1996) Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 77:1303–1310PubMed

32.

Taylor RC, Patel A, Panageas KS, Busam KJ, Brady MS (2007) Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. J Clin Oncol 25:869–875PubMed

33.

Mandalà M, Imberti GL, Piazzalunga D, Belfiglio M, Labianca R, Barberis M, Marchesi L, Poletti P, Bonomi L, Novellino L, Di Biagio K, Milesi A, Guerra U, Tondini C (2009) Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I–II AJCC skin melanoma: Outcome analysis from a single-institution prospectively collected database. Eur J Cancer 45:2537–2545PubMed

34.

Azimi F, Scolyer RA, Rumcheva P, Moncrieff M, Murali R, McCarthy SW, Saw RP, Thompson JF (2012) Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. J Clin Oncol 30:2678–2683PubMed

35.

Clark WH Jr, From L, Bernardino EA, Mihm MC (1969) The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 29:705–727PubMed

36.

Guitart J, Lowe L, Piepkorn M, Prieto VG, Rabkin MS, Ronan SG, Shea CR, Tron VA, White W, Barnhill RL (2002) Histological characteristics of metastasizing thin melanomas: A case–control study of 43 cases. Arch Dermatol 138:603–608PubMed

37.

Blessing K, McLaren KM, McLean A, Davidson P (1990) Thin malignant melanomas (less than 1.5 mm) with metastasis: A histological study and survival analysis. Histopathology 17:389–395PubMed

38.

Morris KT, Busam KJ, Bero S, Patel A, Brady MS (2008) Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. Ann Surg Oncol 15:316–322PubMed

39.

Storr SJ, Safuan S, Mitra A, Elliott F, Walker C, Vasko MJ, Ho B, Cook M, Mohammed RA, Patel PM, Ellis IO, Newton-Bishop JA, Martin SG (2012) Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol 25:493–504PubMedCentralPubMed

40.

Massi D, Puig S, Franchi A, Malvehy J, Vidal-Sicart S, González-Cao M, Baroni G, Ketabchi S, Palou J, Santucci M (2006) Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: A case–control study. J Clin Pathol 59:166–173PubMedCentralPubMed

41.

Xu X, Chen L, Guerry D, Dawson PR, Hwang WT, VanBelle P, Elder DE, Zhang PJ, Ming ME, Schuchter L, Gimotty PA (2012) Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. Clin Cancer Res 18:229–237PubMedCentralPubMed

42.

Doeden K, Ma Z, Narasimhan B, Swetter SM, Detmar M, Dadras SS (2009) Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol 36:772–780PubMed

43.

Xu X, Gimotty PA, Guerry D, Karakousis G, Van Belle P, Liang H, Montone K, Pasha T, Ming ME, Acs G, Feldman M, Barth S, Hammond R, Elenitsas R, Zhang PJ, Elder DE (2008) Lymphatic invasion revealed by multispectral imaging is common in primary melanomas and associates with prognosis. Hum Pathol 39:901–909PubMedCentralPubMed

44.

Valencak J, Heere-Ress E, Kopp T, Schoppmann SF, Kittler H, Pehamberger H (2004) Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma. Eur J Cancer 40:358–364PubMed

45.

Yun SJ, Gimotty PA, Hwang WT, Dawson P, Van Belle P, Elder DE, Elenitsas R, Schuchter L, Zhang PJ, Guerry D, Xu X (2011) High lymphatic vessel density and lymphatic invasion underlie the adverse prognostic effect of radial growth phase regression in melanoma. Am J Surg Pathol 35:235–242PubMedCentralPubMed

46.

Rose AE, Christos PJ, Lackaye D, Shapiro RL, Berman R, Mazumdar M, Kamin H, Osman I, Darvishian F (2011) Clinical relevance of detection of lymphovascular invasion in primary melanoma using endothelial markers D2-40 and CD34. Am J Surg Pathol 35:1441–1449PubMedCentralPubMed

47.

Petersson F, Diwan AH, Ivan D, Gershenwald JE, Johnson MM, Harrell R, Prieto VG (2009) Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol 36:1157–1163PubMed

48.

Cook MG, Green MA, Anderson B, Eggermont AM, Ruiter DJ, Spatz A, Kissin MW, Powell BW, EORTC Melanoma Group (2003) The development of optimal pathological assessment of sentinel lymph nodes for melanoma. J Pathol 200:314–319PubMed

49.

van Akkooi AC, de Wilt JH, Verhoef C, Schmitz PI, van Geel AN, Eggermont AM, Kliffen M (2006) Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? Ann Oncol 17:1578–1585PubMed

50.

van der Ploeg AP, van Akkooi AC, Schmitz PI, Koljenovic S, Verhoef C, Eggermont AM (2010) EORTC melanoma group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam criteria. Eur J Cancer 46:2414–2421PubMed

51.

Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR, Cascinelli N, Cochran AJ, Coit DG, Eggermont AM, Johnson T, Kirkwood JM, Leong SP, McMasters KM, Mihm MC Jr, Morton DL, Ross MI, Sondak VK (2010) Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol 28:2452–2459PubMedCentralPubMed

52.

van der Ploeg AP, van Akkooi AC, Rutkowski P, Nowecki ZI, Michej W, Mitra A, Newton-Bishop JA, Cook M, van der Ploeg IM, Nieweg OE, van den Hout MF, van Leeuwen PA, Voit CA, Cataldo F, Testori A, Robert C, Hoekstra HJ, Verhoef C, Spatz A, Eggermont AM (2011) Prognosis in patients with sentinel node–positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. J Clin Oncol 29:2206–2214PubMed

53.

Alonso SR, Ortiz P, Pollán M, Pérez-Gómez B, Sánchez L, Acuña MJ, Pajares R, Martínez-Tello FJ, Hortelano CM, Piris MA, Rodríguez-Peralto JL (2004) Progression in cutaneous malignant melanoma is associated with distinct expression profiles: A tissue microarray-based study. Am J Pathol 164:193–203PubMedCentralPubMed

54.

Alonso SR, Tracey L, Ortiz P, Pérez-Gómez B, Palacios J, Pollán M, Linares J, Serrano S, Sáez-Castillo AI, Sánchez L, Pajares R, Sánchez-Aguilera A, Artiga MJ, Piris MA, Rodríguez-Peralto JL (2007) A high-throughput study in melanoma identifies epithelial–mesenchymal transition as a major determinant of metastasis. Cancer Res 67:3450–3460PubMed

55.

Berger AJ, Kluger HM, Li N, Kielhorn E, Halaban R, Ronai Z, Rimm DL (2003) Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 63:8103–8107PubMed

56.

Florenes VA, Maelandsmo GM, Faye R, Nesland JM, Holm R (2001) Cyclin a expression in superficial spreading malignant melanomas correlates with clinical outcome. J Pathol 195:530–536PubMed

57.

Florenes VA, Faye RS, Maelandsmo GM, Nesland JM, Holm R (2000) Levels of cyclin D1 and D3 in malignant melanoma: Deregulated cyclin D3 expression is associated with poor clinical outcome in superficial melanoma. Clin Cancer Res 6:3614–3620PubMed

58.

Li Q, Murphy M, Rossi J, Sheehan C, Carlson JA (2004) Skp2 and p27kip1 expression in melanocytic nevi and melanoma: An inverse relationship. J Cutan Pathol 31:633–642PubMed

59.

Niezabitowski A, Czajecki K, Ryś J, Kruczak A, Gruchała A, Wasilewska A, Lackowska B, Sokołowski A, Szklarski W (1999) Prognostic evaluation of cutaneous malignant melanoma: A clinicopathologic and immunohistochemical study. J Surg Oncol 70:150–160PubMed

60.

Rangel J, Torabian S, Shaikh L, Nosrati M, Baehner FL, Haqq C, Leong SP, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2006) Prognostic significance of nuclear receptor coactivator-3 overexpression in primary cutaneous melanoma. J Clin Oncol 24:4565–4569PubMed

61.

Straume O, Akslen LA (2005) Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma. Br J Cancer 93:933–938PubMedCentralPubMed

62.

Straume O, Sviland L, Akslen LA (2000) Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6:1845–1853PubMed

63.

Piras F, Perra MT, Murtas D, Minerba L, Floris C, Maxia C, Demurtas P, Ugalde J, Ribatti D, Sirigu P (2008) Combinations of apoptosis and cell-cycle control biomarkers predict the outcome of human melanoma. Oncol Rep 20:271–277PubMed

64.

Rangel J, Nosrati M, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2008) Novel role for RGS1 in melanoma progression. Am J Surg Pathol 32:1207–1212PubMed

65.

Reschke M, Mihic-Probst D, van der Horst EH, Knyazev P, Wild PJ, Hutterer M, Meyer S, Dummer R, Moch H, Ullrich A (2008) HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14:5188–5197PubMed

66.

Ladstein RG, Bachmann IM, Straume O, Akslen LA (2010) Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer 10:140PubMedCentralPubMed

67.

Ladstein RG, Bachmann IM, Straume O, Akslen LA (2012) Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. J Invest Dermatol 132:1247–1252PubMed

68.

Chen G, Cheng Y, Zhang Z, Martinka M, Li G (2011) Cytoplasmic Skp2 expression is increased in human melanoma and correlated with patient survival. PLoS One 6:e17578PubMedCentralPubMed

69.

Gimotty PA, Van Belle P, Elder DE, Murry T, Montone KT, Xu X, Hotz S, Raines S, Ming ME, Wahl P, Guerry D (2005) Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol 23:8048–8056PubMed

70.

Berger AJ, Davis DW, Tellez C, Prieto VG, Gershenwald JE, Johnson MM, Rimm DL, Bar-Eli M (2005) Automated quantitative analysis of activator protein-2alpha subcellular expression in melanoma tissue microarrays correlates with survival prediction. Cancer Res 65:11185–11192PubMed

71.

Berger AJ, Camp RL, Divito KA, Kluger HM, Halaban R, Rimm DL (2004) Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 64:8767–8772PubMed

72.

Karjalainen JM, Kellokoski JK, Eskelinen MJ, Alhava EM, Kosma VM (1998) Downregulation of transcription factor AP-2 predicts poor survival in stage I cutaneous malignant melanoma. J Clin Oncol 16:3584–3591PubMed

73.

Korabiowska M, Tscherny M, Stachura J, Berger H, Cordon-Cardo C, Brinck U (2002) Differential expression of DNA nonhomologous end-joining proteins Ku70 and Ku80 in melanoma progression. Mod Pathol 15:426–433PubMed

74.

McDermott NC, Milburn C, Curran B, Kay EW, Barry Walsh C, Leader MB (2000) Immunohistochemical expression of nm23 in primary invasive malignant melanoma is predictive of survival outcome. J Pathol 190:157–162PubMed

75.

Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD (2005) nm23 as a prognostic marker in primary cutaneous melanoma: Evaluation using tissue microarray in a patient group with long-term follow-up. Melanoma Res 15:435–440PubMed

76.

Soltani MH, Pichardo R, Song Z, Sangha N, Camacho F, Satyamoorthy K, Sangueza OP, Setaluri V (2005) Microtubule-associated protein 2, a marker of neuronal differentiation, induces mitotic defects, inhibits growth of melanoma cells, and predicts metastatic potential of cutaneous melanoma. Am J Pathol 166:1841–1850PubMedCentralPubMed

77.

Li J, Martinka M, Li G (2008) Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29:1373–1379PubMed

78.

Lin H, Wong RPC, Martinka M, Li G (2009) Loss of SNF5 expression correlates with poor patient survival in melanoma. Clin Cancer Res 15:6404–6411PubMed

79.

Jonsson L, Bergman J, Nodin B, Manjer J, Pontén F, Uhlén M, Jirström K (2011) Low RBM3 protein expression correlates with tumour progression and poor prognosis in malignant melanoma: An analysis of 215 cases from the malmö diet and cancer study. J Transl Med 9:114PubMedCentralPubMed

80.

Jafarnejad SM, Wani AA, Martinka M, Li G (2010) Prognostic significance of Sox4 expression in human cutaneous melanoma and its role in cell migration and invasion. Am J Pathol 177:2741–2752PubMedCentralPubMed

81.

Chen H, Takahara M, Oba J, Xie L, Chiba T, Takeuchi S, Tu Y, Nakahara T, Uchi H, Moroi Y, Furue M (2011) Clinicopathologic and prognostic significance of SATB1 in cutaneous malignant melanoma. J Dermatol Sci 64:39–44PubMed

82.

Divito KA, Berger AJ, Camp RL, Dolled-Filhart M, Rimm DL, Kluger HM (2004) Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 64:8773–8777PubMed

83.

Ekmekcioglu S, Ellerhorst JA, Prieto VG, Johnson MM, Broemeling LD, Grimm EA (2006) Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 119:861–866PubMed

84.

Bachmann IM, Ladstein RG, Straume O, Naumov GN, Akslen LA (2008) Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 8:362PubMedCentralPubMed

85.

Piras F, Murtas D, Minerba L, Ugalde J, Floris C, Maxia C, Colombari R, Perra MT, Sirigu P (2007) Nuclear survivin is associated with disease recurrence and poor survival in patients with cutaneous malignant melanoma. Histopathology 50:835–842PubMed

86.

Zhuang L, Scolyer RA, Lee CS, McCarthy SW, Cooper WA, Zhang XD, Thompson JF, Hersey P (2009) Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma. Histopathology 54:462–470PubMed

87.

Bittner M, Meltzer P, Chen Y, Jiang Y, Seftor E, Hendrix M, Radmacher M, Simon R, Yakhini Z, Ben-Dor A, Sampas N, Dougherty E, Wang E, Marincola F, Gooden C, Lueders J, Glatfelter A, Pollock P, Carpten J, Gillanders E, Leja D, Dietrich K, Beaudry C, Berens M, Alberts D, Sondak V (2000) Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795):536–540PubMed

88.

Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, Benevolo M, Mottolese M, Pescarmona E, Visca P, Natali PG, Giacomini P (2012) Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol 13(5):e205–e211PubMed

89.

Mandruzzato S, Callegaro A, Turcatel G, Francescato S, Montesco MC, Chiarion-Sileni V, Mocellin S, Rossi CR, Bicciato S, Wang E, Marincola FM, Zanovello P (2006) A gene expression signature associated with survival in metastatic melanoma. J Transl Med 4:50PubMedCentralPubMed

90.

Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ, Spatz A, Melanoma Group of the European Organization for Research and Treatment of Cancer (2006) Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98:472–482PubMed

91.

Soikkeli J, Lukk M, Nummela P, Virolainen S, Jahkola T, Katainen R, Harju L, Ukkonen E, Saksela O, Hölttä E (2007) Systematic search for the best gene expression markers for melanoma micrometastasis detection. J Pathol 213:180–189PubMed

92.

Brunner G, Reitz M, Schwipper V, Tilkorn H, Lippold A, Biess B, Suter L, Atzpodien J (2008) Increased expression of the tumor suppressor PLZF is a continuous predictor of long-term survival in malignant melanoma patients. Cancer Biother Radiopharm 23:451–459PubMed

93.

John T, Black MA, Toro TT, Leader D, Gedye CA, Davis ID, Guilford PJ, Cebon JS (2008) Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 14:5173–5180PubMed

94.

Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A, Sarasin A (2008) High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27:565–573PubMed

95.

Bogunovic D, O'Neill DW, Belitskaya-Levy I, Vacic V, Yu YL, Adams S, Darvishian F, Berman R, Shapiro R, Pavlick AC, Lonardi S, Zavadil J, Osman I, Bhardwaj N (2009) Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival. Proc Natl Acad Sci U S A 106:20429–20434PubMedCentralPubMed

96.

Conway C, Mitra A, Jewell R, Randerson-Moor J, Lobo S, Nsengimana J, Edward S, Sanders DS, Cook M, Powell B, Boon A, Elliott F, de Kort F, Knowles MA, Bishop DT, Newton-Bishop J (2009) Gene expression profiling of paraffin-embedded primary melanoma using the DASL assay identifies increased osteopontin expression as predictive of reduced relapse-free survival. Clin Cancer Res 15:6939–6946PubMedCentralPubMed

97.

Haqq C, Nosrati M, Sudilovsky D, Crothers J, Khodabakhsh D, Pulliam BL, Federman S, Miller JR 3rd, Allen RE, Singer MI, Leong SP, Ljung BM, Sagebiel RW, Kashani-Sabet M (2005) The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102:6092–6097PubMedCentralPubMed

98.

Caramuta S, Egyházi S, Rodolfo M, Witten D, Hansson J, Larsson C, Lui WO (2010) MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 130:2062–2070PubMed

99.

Segura MF, Belitskaya-Lévy I, Rose AE, Zakrzewski J, Gaziel A, Hanniford D, Darvishian F, Berman RS, Shapiro RL, Pavlick AC, Osman I, Hernando E (2010) Melanoma microRNA signature predicts post-recurrence survival. Clin Cancer Res 16:1577–1586PubMed

100.

Mauerer A, Roesch A, Hafner C, Stempfl T, Wild P, Meyer S, Landthaler M, Vogt T (2011) Identification of new genes associated with melanoma. Exp Dermatol 20:502–507PubMed

101.

Ferrier CM, Suciu S, van Geloof WL, Straatman H, Eggermont AM, Koops HS, Kroon BB, Lejeune FJ, Kleeberg UR, van Muijen GN, Ruiter DJ (2000) High tPA-expression in primary melanoma of the limb correlates with good prognosis. Br J Cancer 83:1351–1359PubMedCentralPubMed

102.

Ilmonen S, Jahkola T, Turunen JP, Muhonen T, Asko-Seljavaara S (2004) Tenascin-C in primary malignant melanoma of the skin. Histopathology 45:405–411PubMed

103.

Karjalainen JM, Tammi RH, Tammi MI, Eskelinen MJ, Agren UM, Parkkinen JJ, Alhava EM, Kosma VM (2000) Reduced level of CD44 and hyaluronan associated with unfavorable prognosis in clinical stage I cutaneous melanoma. Am J Pathol 157:957–965PubMedCentralPubMed

104.

Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD (2006) CD44v3 levels in primary cutaneous melanoma are predictive of prognosis: assessment by the use of tissue microarray. Int J Cancer 118:1460–1464PubMed

105.

Pacifico MD, Grover R, Richman PI, Buffa F, Daley FM, Wilson GD (2005) Identification of P-cadherin in primary melanoma using a tissue microarrayer: Prognostic implications in a patient cohort with long-term follow up. Ann Plast Surg 55:316–320PubMed

106.

Pacifico MD, Grover R, Richman PI, Daley FM, Buffa F, Wilson GD (2005) Development of a tissue array for primary melanoma with long-term follow-up: Discovering melanoma cell adhesion molecule as an important prognostic marker. Plast Reconstr Surg 115:367–375PubMed

107.

Pearl RA, Pacifico MD, Richman PI, Wilson GD, Grover R (2008) Stratification of patients by melanoma cell adhesion molecule (MCAM) expression on the basis of risk: Implications for sentinel lymph node biopsy. J Plast Reconstr Aesthet Surg 61:265–271PubMed

108.

Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, Miller JR 3rd, Sagebiel RW, Kashani-Sabet M (2008) Osteopontin as a molecular prognostic marker for melanoma. Cancer 112:144–150PubMed

109.

Scala S, Ottaiano A, Ascierto PA, Cavalli M, Simeone E, Giuliano P, Napolitano M, Franco R, Botti G, Castello G (2005) Expression of CXCR4 predicts poor prognosis in patients with malignant melanoma. Clin Cancer Res 11:1835–1841PubMed

110.

Thies A, Schachner M, Moll I, Berger J, Schulze HJ, Brunner G, Schumacher U (2002) Overexpression of the cell adhesion molecule L1 is associated with metastasis in cutaneous malignant melanoma. Eur J Cancer 38:1708–1716PubMed

111.

Thies A, Moll I, Berger J, Wagener C, Brümmer J, Schulze HJ, Brunner G, Schumacher U (2002) CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol 20:2530–2536PubMed

112.

Weinlich G, Eisendle K, Hassler E, Baltaci M, Fritsch PO, Zelger B (2006) Metallothionein—overexpression as a highly significant prognostic factor in melanoma: A prospective study on 1270 patients. Br J Cancer 94:835–841PubMedCentralPubMed

113.

Weinlich G, Topar G, Eisendle K, Fritsch PO, Zelger B (2007) Comparison of metallothionein-overexpression with sentinel lymph node biopsy as prognostic factors in melanoma. J Eur Acad Dermatol Venereol 21:669–677PubMed

114.

Bachmann IM, Ladstein RG, Straume O, Naumov GN, Akslen LA (2008) Tumor necrosis is associated with increased alpha(v)beta(3) integrin expression and poor prognosis in nodular cutaneous melanomas. BMC Cancer 8:1–10

115.

Boone B, Van Gele M, Lambert J, Haspeslagh M, Brochez L (2009) The role of RhoC in growth and metastatic capacity of melanoma. J Cutan Pathol 36:629–636PubMed

116.

Kreizenbeck GM, Berger AJ, Subtil A, Rimm DL, Gould Rothberg BE (2008) Prognostic significance of cadherin-based adhesion molecules in cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 17:949–958PubMedCentralPubMed

117.

Buljan M, Šitum M, Tomas D, Milošević M, Krušlin B (2011) Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol 25:1174–1181PubMed

118.

Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T (2013) E- to N-cadherin switch in melanoma is associated with decreased expression of PTEN and cancer progression. Br J Dermatol. doi:10.1111/bjd.12426 PubMed

119.

Bachmann IM, Puntervoll HE, Otte AP, Akslen LA (2008) Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 21:583–590PubMed

120.

Straume O, Jackson DG, Akslen LA (2003) Cutaneous melanoma and presence of low-grade lymphangiogenesis in independent prognostic impact of lymphatic vessel density. Clin Cancer Res 9:250–256PubMed

121.

Zhuang L, Scolyer RA, Murali R, McCarthy SW, Zhang XD, Thompson JF, Hersey P (2010) Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins. Mod Pathol 23:45–53PubMed

122.

Hofbauer GF, Burkhart A, Schuler G, Dummer R, Burg G, Nestle FO (2004) High frequency of melanoma-associated antigen or HLA class I loss does not correlate with survival in primary melanoma. J Immunother 27:73–78PubMed

123.

Svobodová S, Browning J, MacGregor D, Pollara G, Scolyer RA, Murali R, Thompson JF, Deb S, Azad A, Davis ID, Cebon JS (2011) Cancer-testis antigen expression in primary cutaneous melanoma has independent prognostic value comparable to that of breslow thickness, ulceration and mitotic rate. Eur J Cancer 47:460–469PubMed

124.

Kashani-Sabet M, Venna S, Nosrati M, Rangel J, Sucker A, Egberts F, Baehner FL, Simko J, Leong SP, Haqq C, Hauschild A, Schadendorf D, Miller JR 3rd, Sagebiel RW (2009) A multimarker prognostic assay for primary cutaneous melanoma. Clin Cancer Res 15:6987–6992PubMedCentralPubMed

125.

Gould Rothberg BE, Berger AJ, Molinaro AM, Subtil A, Krauthammer MO, Camp RL, Bradley WR, Ariyan S, Kluger HM, Rimm DL (2009) Melanoma prognostic model using tissue microarrays and genetic algorithms. J Clin Oncol 27:5772–5780PubMedCentralPubMed

126.

Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, Carter SL, Stewart C, Mermel CH, Roberts SA, Kiezun A, Hammerman PS, McKenna A, Drier Y, Zou L, Ramos AH, Pugh TJ, Stransky N, Helman E, Kim J, Sougnez C, Ambrogio L, Nickerson E, Shefler E, Cortés ML, Auclair D, Saksena G, Voet D, Noble M, DiCara D, Lin P, Lichtenstein L, Heiman DI, Fennell T, Imielinski M, Hernandez B, Hodis E, Baca S, Dulak AM, Lohr J, Landau DA, Wu CJ, Melendez-Zajgla J, Hidalgo-Miranda A, Koren A, McCarroll SA, Mora J, Lee RS, Crompton B, Onofrio R, Parkin M, Winckler W, Ardlie K, Gabriel SB, Roberts CW, Biegel JA, Stegmaier K, Bass AJ, Garraway LA, Meyerson M, Golub TR, Gordenin DA, Sunyaev S, Lander ES, Getz G (2013) Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499(7457):214–218PubMedCentralPubMed

127.

Flaherty KT, Hodi FS, Bastian BC (2010) Mutation-driven drug development in melanoma. Curr Opin Oncol 22:178–183PubMedCentralPubMed

128.

Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949–954PubMed

129.

Safaee Ardekani G, Jafarnejad SM, Tan L, Saeedi A, Li G (2012) The prognostic value of BRAF mutation in colorectal cancer and melanoma: A systematic review and meta-analysis. PLoS One 7:e47054PubMedCentralPubMed

130.

Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17:229–235PubMedCentralPubMed

131.

Edlundh-Rose E, Egyházi S, Omholt K, Månsson-Brahme E, Platz A, Hansson J, Lundeberg J (2006) BRAF mutations in melanoma tumours in relation to clinical characteristics: A study based on mutation screening by pyrosequencing. Melanoma Res 16:471–478PubMed

132.

Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29:1239–1246PubMed

133.

Si L, Kong Y, Xu X (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: Large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48:94–100PubMed

134.

Devitt B, Liu W, Salemi R, Wolfe R, Kelly J, Tzen CY, Dobrovic A, McArthur G (2011) Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res 24:666–672PubMed

135.

Mann GJ, Pupo GM, Campain AE, Carter CD, Schramm SJ, Pianova S, Gerega SK, De Silva C, Lai K, Wilmott JS, Synnott M, Hersey P, Kefford RF, Thompson JF, Yang YH, Scolyer RA (2013) BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma. J Invest Dermatol 133:509–517PubMed

Title: Tissue prognostic biomarkers in primary cutaneous melanoma
Authors: Mario Mandalà
Daniela Massi
Publication date: 01-03-2014
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 3/2014
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-013-1526-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tissue prognostic biomarkers in primary cutaneous melanoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2014

Biomarkers in renal cancer

Prognostic biomarkers: an introduction

Testicular cancer: biology and biomarkers

Prognostic biomarkers in endometrial and ovarian carcinoma

Molecular tests as prognostic factors in breast cancer

Prognostic biomarkers in colorectal cancer: where do we stand?